Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Pidotimune
(United States) [Available] ,Immulina
(United States) [Available]Synonyms :
pidotimod
Class :
Vaccines, Immunomodulatory agent
Brand Name :
Pidotimune
(United States) [Available] ,Immulina
(United States) [Available]Synonyms :
pidotimod
Class :
Vaccines, Immunomodulatory agent
Dosage Forms & StrengthsÂ
Tablet Â
400mgÂ
800mgÂ
No data is availableÂ
Refer to the adult dosingÂ
sipuleucel-T: they may decrease the therapeutic effect of immunostimulants
leflunomide: they may increase the immunosuppressive effect of immunostimulants
denosumab: they may increase the immunosuppressive effect of immunostimulants
baricitinib: they may enhance the immunosuppressive effect of immunostimulants
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
may reduce the therapeutic efficacy of pidotimod
cladribine: they may increase the immunosuppressive effect of immunostimulants
deucravacitinib: they may increase the immunosuppressive effect of immunostimulants
immunostimulants: they may increase the toxic effect of nadofaragene firadenovec
natalizumab: they may increase the immunosuppressive effect of immunostimulants
pimecrolimus: they may increase the immunosuppressive effect of immunostimulants
ruxolitinib: they may increase the immunosuppressive effect of immunostimulants
talimogene laherparepvec: they may increase the toxic effect of immunostimulants
tofacitinib: they may increase the immunosuppressive effect of immunostimulants
upadacitinib: they may increase the immunosuppressive effect of immunostimulants
antithymocyte globulin equineÂ
antithymocyte globulin: they may increase the toxic effect of immunostimulants
abrocitinib: they may increase the immunosuppressive effect of immunostimulants
yellow fever vaccine: they may increase the toxic effect of immunostimulants
it decreases the rate of elimination of pidotimod
it decreases the rate of elimination of pidotimod acemetacin
it decreases the rate of elimination of pidotimod
it decreases the rate of elimination of pidotimod
it decreases the rate of elimination of pidotimod
it decreases the rate of elimination of pidotimod
it decreases the rate of elimination of pidotimod
it decreases the rate of elimination of pidotimod
it decreases the rate of elimination of pidotimod
it decreases the rate of elimination of pidotimod
it decreases the rate of elimination of pidotimod
it decreases the rate of elimination of pidotimod
may decrease the therapeutic effect when combined with pidotimod
may decrease the therapeutic effect when combined with pidotimod
may decrease the therapeutic effect when combined with pidotimod
may decrease the therapeutic effect when combined with pidotimod
may decrease the therapeutic effect when combined with pidotimod
may decrease the therapeutic effect when combined with pidotimod
may decrease the therapeutic effect when combined with pidotimod
may decrease the therapeutic effect when combined with pidotimod
pidotimod: they may decrease the therapeutic effect of immunostimulants
pidotimod: they may decrease the therapeutic effect of immunostimulants
pidotimod: they may decrease the therapeutic effect of immunostimulants
pidotimod: they may decrease the therapeutic effect of immunostimulants
pidotimod: they may decrease the therapeutic effect of immunostimulants
trimetrexate may diminish the therapeutic effects of pidotimod
pemetrexed may diminish the therapeutic effects of pidotimod
pralatrexate may diminish the therapeutic effects of pidotimod
oncologic agents may diminish the therapeutic effects of pidotimod
immunosuppressive drugs may reduce the therapeutic effects of pidotimod
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect
may decrease the therapeutic effect of Immunosuppressants
may decrease the therapeutic effect of Immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
brincidofovir: they may decrease the therapeutic effect of immunostimulants
inebilizumab: they may increase the immunosuppressive effect of immunostimulants
ocrelizumab: they may increase the immunosuppressive effect of immunostimulants
ofatumumab: they may increase the immunosuppressive effect of immunostimulants
pidotimod: they may decrease the therapeutic effect of immunostimulants
ublituximab: they may increase the immunosuppressive effect of immunostimulants
Actions and Spectrum:Â
pidotimod works by inhibiting the tumor necrosis factor α, which increases the ERK i.e., extracellular-related kinase phosphorylation. pidotimod increases the dendritic cell maturation that causes antigen presence in naĂŻve Th-cells.Â
Frequency not definedÂ
NauseaÂ
Stomach bleedingÂ
Black Box Warning:Â
NoneÂ
Contraindication/Caution:Â
Contraindications:Â
Cautions:Â
Pregnancy consideration:Â Â
The drug should be avoided during pregnancy.Â
Breastfeeding warnings:Â Â
The drug is not indicated during lactation. Â
Pregnancy category:Â
Category A: Well-controlled and satisfactory studies show no risk to the fetus in the initial or later trimester.Â
Category B: There was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: There was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.   Â
Category N: No data is available for the drug under this category.Â
Pharmacology:Â Â
pidotimod works by inhibiting the tumor necrosis factor α, which increases the ERK, i.e., extracellular-related kinase phosphorylation. pidotimod increases the dendritic cell maturation that causes antigen presence in naĂŻve Th-cells.Â
Pharmacodynamics:Â
pidotimod works by inhibiting the tumor necrosis factor α, which increases the ERK i.e. extracellular-related kinase phosphorylation.Â
pidotimod increases the dendritic cell maturation that causes antigen presence in naĂŻve Th-cells.Â
Pharmacokinetics:Â
Absorption:Â
Bioavailabilty-45%Â Â
Distribution:Â Â
The half-life is 4 hoursÂ
Metabolism:Â
Not availableÂ
Elimination and Excretion:Â
95% of the drug is eliminated in urineÂ
Administration:Â
The pidotimod is taken orally as a tablet or sometimes given intravenously.
Patient information leafletÂ
Generic Name: pidotimodÂ
Pronounced as: pih-do-tih-modÂ
Why do we use pidotimod?Â
pidotimod is used to increase the immunity that gets reduced due to various physiological conditions.Â
It is involved in various adaptive and innate responses. Â
pidotimod is also considered efficacious in the treatment of respiratory infections.Â
It is used as an immunomodulatory agent to stimulate immunity. Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
